Oncology Corporate Profile
Cold Genesys, Inc. is a privately-held, clinical-stage oncolytic viral immunotherapy company with its lead product CG0070 now in an integrated Phase II/III clinical trial for bladder cancer. CG0070 is a conditionally replication-competent adenovirus, containing an E2F promoter in the viral E1A region that drives the expression of GM-CSF. CGI also has developed n-dodecyl-D-maltoside to specifically enhance viral transduction in cancer cells. CG0070 was previously tested in a Phase I/II trial of 35 patients with non-muscle invasive bladder cancer in 2008.
Website: http://coldgenesys.com/
Brand / Product | Class | Area of Study | Phase | Partnership |
---|---|---|---|---|
CG0070 | oncolytic virus | Bladder cancer | III | |
CG0070 (+ immune checkpoint moduator) | oncolytic virus | Bladder cancer | I | |
CG0070 (+ immune checkpoint moduator) | oncolytic virus | Various cancer types | I | |
CG0161 | anti-CTLA-4 antibody | Various cancer types | Preclinical |
View additional information on product candidates here »